Cell cycle checkpoint models for cellular pharmacology of paclitaxel and platinum drugs

AAPS Journal

Volumn 10, Issue 1, 2008, Pages 15-34

  El Kareh, Ardith W ^a   Labes, Rachel E ^a   Secomb, Timothy W ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Carboplatin; Cellular pharmacodynamics; Chemotherapy; Cisplatin; Dose response; Mathematical model; Oxaliplatin; Paclitaxel; Pharmacology; Taxol

Indexed keywords

CARBOPLATIN; CISPLATIN; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING KINETICS; CANCER CELL CULTURE; CELL CYCLE; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LONG TERM EXPOSURE; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; NORMAL DISTRIBUTION; PHARMACODYNAMICS;

CELL CYCLE; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, BIOLOGICAL; PACLITAXEL; PLATINUM COMPOUNDS;

EID: 51249114777     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-007-9003-6     Document Type: Article

References (76)

1. E. Briasoulis, V. Karavasilis, E. Tzamakou, C. Haidou, C. Piperidou, and N. Pavlidis. Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: Results of a dose-escalation study. Anticancer Drugs 13(5):481-489 (2002).
2. D. Schrag, H. S. Garewal, H. J. Burstein, D. J. Samson, D. D. Von Hoff, and M. R. Somerfield. American Society of Clinical Oncology technology assessment: Chemotherapy sensitivity and resistance assays. J. Clin. Oncol. 22(17):3631-3638 (2004).
3. A. W. El-Kareh, and T. W. Secomb. Theoretical analyses and simulations of anticancer drug delivery. In D. M. Brown (ed.), Drug Delivery Systems in Cancer Therapy, Humana Press, Clifton, NJ, 2003, pp. 25-41.
4. H. Eichholtz-Wirth. Dependence of the cytostatic effect of adriamycin on drug concentration and exposure time in vitro. Br. J. Cancer 41(6):886-891 (1980).
5. S. Ozawa, Y. Sugiyama, Y. Mitsuhashi, T. Kobayashi, and M. Inaba. Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration-time product. Cancer Chemother. Pharmacol. 21 (3):185-190 (1988).
6. A. W. El Kareh, and T. W. Secomb. Two-mechanism peak concentration model for cellular pharmacodynamics of doxorubicin. Neoplasia 7(7):705-713 (2005).
7. H. E. Skipper. The effects of chemotherapy on the kinetics of leukemic cell behavior. Cancer Res. 25(9):1544-1550 (1965).
8. D. J. Adams. In Vitro pharmacodynamic assay for cancer drug development - application to crisnatol, a new Dna intercalator. Cancer Res. 49(23):6615-6620 (1989).
9. N. J. Millenbaugh, M. G. Wientjes, and J. L. S. Au. A pharmacodynamic analysis method to determine the relative importance of drug concentration and treatment time on effect. Cancer Chemother. Pharmacol. 45(4):265-272 (2000).
10. L. M. Levasseur, H. K. Slocum, Y. M. Rustum, and W. R. Greco. Modeling of the time-dependency of in vitro drug cytotoxicity and resistance. Cancer Res. 58(24):5749-5761 (1998).
11. S. N. Gardner. A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs. Cancer Res. 60(5):1417-1425 (2000).
12. A. W. El-Kareh, and T. W. Secomb. A mathematical model for cisplatin cellular pharmacodynamics. Neoplasia 5(2):161-169 (2003).
13. J. L. S. Au, D. Li, Y. B. Gan, X. Gao, A. L. Johnson, J. Johnston, et al. Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. Cancer Res. 58 (10):2141-2148 (1998).
14. R. E. Eliaz, S. Nir, C. Marty, and F. C. Szoka. Determination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes. Cancer Res. 64(2):711-718 (2004).
15. P. Vrignaud, D. Londosgagliardi, and J. Robert. Cellular pharmacology of doxorubicin in sensitive and resistant rat glioblastoma cells in culture. Oncology 43(1):60-66 (1986).
16. H. Minderman, S. S. Cao, and Y. M. Rustum. Rational design of irinotecan administration based on preclinical models. Oncology (New York) 12(8):22-30 (1998).
17. P. G. Parsons. Dependence on treatment time of melphalan resistance and Dna cross-linking in human-melanoma cell-lines. Cancer Res. 44(7):2773-2778 (1984).
18. E. D. Lobo, and J. P. Balthasar. Pharmacodynamic modeling of chemotherapeutic effects: Application of a transit compartment model to characterize methotrexate effects in vitro. AAPS PharmSci 4(4):42-44 (2002).
19. Y. Miyagi, K. Kawanishi, Y. Miyagi, S. Yamada, J. Yamamoto, J. Kodama, et al. Cytocidal effect and DNA damage of nedaplatin: A mathematical model and analysis of experimental data. Cancer Chemother. Pharmacol. 47 (3):229-235 (2001).
20. M. Simeoni, P. Magni, C. Cammia, G. De Nicolao, V. Croci, E. Pesenti, et al. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res. 64(3):1094-1101 (2004).
21. M. A. Shah, and G. K. Schwartz. Cell cycle-mediated drug resistance: An emerging concept in cancer therapy. Clin. Cancer Res. 7(8):2168-2181 (2001).
22. D. L. Evans, M. Tilby, and C. Dive. Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and Dna adduct formation. Cancer Res. 54(6):1596-1603 (1994).
23. R. C. Jackson. The problem of the quiescent cancer cell. Adv. Enzyme Regul. 29:27-46 (1989).
24. M. T. Dimancheboitrel, C. Garrido, and B. Chauffert. Kinetic resistance to anticancer agents. Cytotechnology 12(1-3):347-356 (1993).
25. S. Masunaga, K. Ono, H. Hori, M. Akaboshi, K. Kawai, and M. Suzuki, et al. Enhancement of cisplatin sensitivity of quiescent cells in solid tumors by combined treatment with tirapazamine and low-temperature hyperthermia. Radiat. Med. 16(6):441-448 (1998).
26. A. Swierniak, A. Polanski, and M. Kimmel. Optimal control problems arising in cell-cycle-specific cancer chemotherapy. Cell Prolif. 29 (3):117-139 (1996).
27. W. J. Jusko. Pharmacodynamic model for cell-cycle-specific chemotherapeutic agents. J. Pharmacokinet. Biopharm. 1 (3):175-200 (1973).
28. S. Ozawa, Y. Sugiyama, J. Mitsuhashi, and M. Inaba. Kinetic-analysis of cell killing effect induced by cytosine-arabinoside and cisplatin in relation to cell-cycle phase specificity in human-colon cancer and Chinese-hamster cells. Cancer Res. 49(14):3823-3828 (1989).
29. K. R. Fister, and J. C. Panetta. Optimal control applied to cell-cycle-specific cancer chemotherapy. SIAM J. Appl. Math. 60(3):1059-1072 (2000).
30. K. L. Donaldson, G. L. Goolsby, and A. F. Wahl. Cytotoxicity of the anticancer agents cisplatin and taxol during cell-proliferation and the cell-cycle. Int. J. Cancer 57(6):847-855 (1994).
31. G. Sena, C. Onado, P. Cappella, F. Montalenti, and P. Ubezio. Measuring the complexity of cell cycle arrest and killing of drugs: Kinetics of phase-specific effects induced by Taxol. Cytometry 37 (2):113-124 (1999).
32. M. O. Trielli, P. R. Andreassen, F. B. Lacroix, and R. L. Margolis. Differential taxol-dependent arrest of transformed and nontransformed cells in the G1 phase of the cell cycle, and specific-related mortality of transformed cells. J. Cell Biol. 135 (3):689-700 (1996).
33. V. Troger, J. L. Fischel, P. Formento, J. Gioanni, and G. Milano. Effects of prolonged exposure to cisplatin on cytotoxicity and intracellular drug concentration. Eur. J. Cancer 28(1):82-86 (1992).
34. H. J. Kuh, S. H. Jang, M. G. Wientjes, and J. L. Au. Computational model of intracellular pharmacokinetics of paclitaxel. J. Pharmacol. Exp. Ther. 293(3):761-770 (2000).
35. A. Riccardi, T. Servidei, A. Tornesello, P. Puggioni, S. Mastrangelo, C. Rumi, et al. Cytotoxicity of paclitaxel and docetaxel in human neuroblastoma cell-lines. Eur. J. Cancer 31A(4):494-499 (1995).
36. S. B. Hassan, E. Jonsson, R. Larsson, and M. O. Karlsson. Model for time dependency of cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action. J. Pharmacol. Exp. Ther. 299(3):1140-1147 (2001).
37. K. L. Donaldson, G. Goolsby, P. A. Kiener, and A. F. Wahl. Activation of P34(Cdc2) coincident with taxol-induced apoptosis. Cell Growth Differ. 5(10):1041-1050 (1994).
38. K. Torres, and S. B. Horwitz. Mechanisms of taxol-induced cell death are concentration dependent. Cancer Res. 58(16):3620-3626 (1998).
39. D. H. Kern, C. R. Morgan, and S. U. Hildebrandzanki. In Vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine - synergy of antitumor-activity with cis-diamminedichloroplatinum(Ii). Cancer Res. 48(1):117-121 (1988).
40. S. Hector, W. Bolanowska-Higdon, J. Zdanowicz, S. Hitt, and L. Pendyala. In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother. Pharmacol. 48(5):398-406 (2001).
41. M. Mishima, G. Samimi, A. Kondo, X. Lin, and S. B. Howell. The cellular pharmacology of oxaliplatin resistance. Eur. J. Cancer. 38(10):1405-1412 (2002).
42. S. P. Binks, and M. Dobrota. Kinetics and mechanism of uptake of platinum-based pharmaceuticals by the rat small-intestine. Biochem. Pharmacol. 40(6):1329-1336 (1990).
43. A. Ghezzi, M. Aceto, C. Cassino, E. Gabano, and D. Osella. Uptake of antitumor platinum(II)-complexes by cancer cells, assayed by inductively coupled plasma mass spectrometry (ICP-MS). J. Inorg. Biochem. 98(1):73-78 (2004).
44. E. Pereira-Maia, and A. Garnier-Suillerot. Impaired hydrolysis of cisplatin derivatives to aquated species prevents energy-dependent uptake in GLC4 cells resistant to cisplatin. J. Biol. Inorg. Chem. 8(6):626-634 (2003).
45. H. T. Rupniak, R. D. Whelan, and B. T. Hill. Concentration and time-dependent inter-relationships for antitumour drug cytotoxicities against tumour cells in vitro. Int. J. Cancer 32(1):7-12 (1983).
46. N. Kurihara, T. Kubota, Y. Hoshiya, Y. Otani, K. Kumai, and M. Kitajima. Antitumor activity of cis-diamminedichloroplatinum (II) depends on its time x concentration product against human gastric cancer cell lines in vitro. J. Surg. Oncol. 60(4):238-241 (1995).
47. M. Kornmann, H. Fakler, U. Butzer, H. G. Beger, and K. H. Link. Oxaliplatin exerts potent in vitro cytotoxicity in colorectal and pancreatic cancer cell lines and liver metastases. Anticancer Res. 20(5A):3259-3264 (2000).
48. M. Q. Mohammed, and S. Retsas. Oxaliplatin is active in vitro against human melanoma cell lines: Comparison with cisplatin and carboplatin. Anticancer Drugs 11(10):859-863 (2000).
49. K. W. Vugrin, L. P. Swiler, R. M. Roberts, N. J. Stucky-Mack, and S. P. Sullivan. Confidence region estimation techniques for nonlinear regression: Three case studies. SAND2005-6893. 1-10-2005. Albuquerque NM, Sandia National Laboratories. Sandia Report.
50. D. R. Siwak, S. Shishodia, B. B. Aggarwal, and R. Kurzrock. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of I kappa B kinase and nuclear factor KB activity and are independent of the B-Raf/mitogen-activated/ extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer 104(4):879-890 (2005).
51. A. Photiou, M. N. Sheikh, D. Bafaloukos, and S. Retsas. Antiproliferative activity of vinorelbine (navelbine) against 6 human-melanoma cell-lines. J. Cancer Res. Clin. Oncol. 118 (4):249-254 (1992).
52. M. Derenzini, L. Montanaro, D. Trere, A. Chilla, P. L. Tazzari, F. Dall'Olio, et al. Thymidylate synthase protein expression and activity are related to the cell proliferation rate in human cancer cell lines. J. Clin. Pathol.: Mol. Pathol. 55(5):310-314 (2002).
53. T. Ma, Z. G. Zhu, Y. B. Ji, Y. Zhang, Y. Y. Yu, B. Y. Liu, et al. Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2′-deoxyuridine. World J. Gastroenterol. 10(2):172-176 (2004).
54. S. Akiyama, H. Amo, T. Watanabe, M. Matsuyama, J. Sakamoto, M. Imaizumi, et al. Characteristics of 3 human gastric-cancer cell-lines, Nu-Gc-2, Nu-Gc-3 and Nu-Gc-4. Jpn. J. Surg. 18(4):438-446 (1988).
55. R. T. Morgan, L. K. Woods, G. E. Moore, L. A. Quinn, L. Mcgavran, and S. G. Gordon. Human cell-line (Colo 357) of metastatic pancreatic adenocarcinoma. Int. J. Cancer 25 (5):591-598 (1980).
56. K. Yao, J. A. Gietema, S. Shida, M. Selvakumaran, X. Fonrose, N. B. Haas, et al. In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo. Br. J. Cancer 93(12):1356-1363 (2005).
57. Z. H. Chen, O. I. Olopade, and T. M. Savarese. Expression of methylthioadenosine phosphorylase cDNA in p16(-), MTAP(-) malignant cells: Restoration of methylthioadenosine phosphorylase-dependent salvage pathways and alterations of sensitivity to inhibitors of purine de novo synthesis. Mol. Pharmacol. 52(5):903-911 (1997).
58. K. A. Tacka, D. Szalda, A. K. Souid, J. Goodisman, and J. C. Dabrowiak. Experimental and theoretical studies on the pharmacodynamics of cisplatin in Jurkat cells. Chem. Res. Toxicol. 17(11):1434-1444 (2004).
59. L. B. Sheiner, and S. L. Beal. Some suggestions for measuring predictive performance. J. Pharmacokinet. Biopharm. 9 (4):503-512 (1981).
60. S. H. Tseng, M. S. Bobola, M. S. Berger, and J. R. Silber. Characterization of paclitaxel (Taxol) sensitivity in human glioma- and medulloblastoma-derived cell lines. Neuro-oncol. 1 (2):101-108 (1999).
61. M. J. P. Welters, A. M. J. FichtingerSchepman, R. A. Baan, M. A. J. A. Hermsen, W. J. F. VanderVijgh, J. Cloos, et al. Relationship between the parameters cellular differentiation, doubling time and platinum accumulation and cisplatin sensitivity in a panel of head and neck cancer cell lines. Int. J. Cancer 71(3):410-415 (1997).
62. M. Jackel, and P. Kopfmaier. Influence of cisplatin on cell-cycle progression in xenografted human head and neck carcinomas. Cancer Chemother. Pharmacol. 27(6):464-471 (1991).
63. M. C. Jackel, R. TauschTreml, and P. Kopfmaier. Cytokinetic effects of cisplatin on diverse human head and neck carcinomas in vitro: Dependence on the tumor sensitivity to cisplatin. J. Cancer Res. Clin. Oncol. 122(10):596-602 (1996).
64. E. Pasquier, M. Carre, B. Pourroy, L. Camoin, O. Rebai, C. Briand, et al. Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol. Cancer Ther. 3(10):1301-1310 (2004).
65. H. Schuldes, S. Bade, J. Knobloch, and D. Jonas. Loss of in vitro cytotoxicity of cisplatin after storage as stock solution in cell culture medium at various temperatures. Cancer 79(9):1723-1728 (1997).
66. I. Ringel, and S. B. Horwitz. Taxol is converted to 7-epitaxol, a biologically-active isomer, in cell-culture medium. J. Pharmacol. Exp. Ther. 242(2):692-698 (1987).
67. A. Iliadis, and D. Barbolosi. Optimizing drug regimens in cancer chemotherapy by an efficacy-toxicity mathematical model. Comput. Biomed. Res. 33(3):211-226 (2000).
68. R. B. Martin, M. E. Fisher, R. F. Minchin, and K. L. Teo. A mathematical model of cancer chemotherapy with an optimal selection of parameters. Math. Biosci. 99 (2):205-230 (1990).
69. S. Z. Zhang, K. S. Lovejoy, J. E. Shima, L. L. Lagpacan, Y. Shu, A. Lapuk, et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 66(17):8847-8857 (2006).
70. A. M. Fichtinger-Schepman, F. J. Dijt, P. Bedford, A. T. van Oosterom, B. T. Hill, and F. Berends. Induction and removal of cisplatin-DNA adducts in human cells in vivo and in vitro as measured by immunochemical techniques. IARC Sci. Publ. 89:321-328 (1988).
71. B. Koberle, K. A. Grimaldi, A. Sunters, J. A. Hartley, L. R. Kelland, and J. R. W. Masters. DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int. J. Cancer 70(5):551-555 (1997).
72. G. Samimi, and S. B. Howell. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters. Cancer Chemother. Pharmacol. 57(6):781-788 (2006).
73. P. J. Sadler, and Z. J. Guo. Metal complexes in medicine: Design and mechanism of action. Pure Appl. Chem. 70(4):863-871 (1998).
74. G. G. Steel, and M. J. Peckham. Exploitable mechanisms in combined radiotherapy-chemotherapy - concept of additivity. Int. J. Radiat. Oncol. Biol. Phys. 5(1):85-91 (1979).
75. S. Loewe. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3(6):285-290 (1953).
76. D. J. Adams, P. J. Watkins, V. C. Knick, R. L. Tuttle, and K. W. Bair. Evaluation of arylmethylaminopropanediols by a novel in vitro pharmacodynamic assay: Correlation with antitumor activity in vivo. Cancer Res. 50(12):3663-3669 (1990).